ImmunoGen's lead armed antibody falters in key ovarian cancer test as a monotherapy — shares crash
ImmunoGen’s lead armed antibody — mirvetuximab soravtansine — has failed a late-stage study as a monotherapy in third line platinum-resistant ovarian cancer patients, a miss that could derail studies testing the drug as part of a combo.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.